By Fineline Cube 
China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.
Mechanism of Action
Ebdarokimab works by binding to the p40 subunit of IL-12 and IL-23, blocking their interaction with cell surface receptors. This action reduces the release of cytokines like interferon-γ, TNF-α, and IL-17 from T cells, thereby modulating the immune response that drives psoriasis.
Clinical Profile and Patient Benefits
As the first and only domestically developed IL-12/IL-23 mAb in China, ebdarokimab has demonstrated significant clinical efficacy and excellent safety. Administered only four times a year, the drug improves medication compliance and leads to long-term stable improvements in treatment efficacy and quality of life for patients.-Fineline Info & Tech